Literature DB >> 21701075

Glucose-incretin interaction revisited.

Hiroaki Ishii1, Yoshihiko Sato, Masahiro Takei, Shinichi Nishio, Mitsuhisa Komatsu.   

Abstract

Pancreatic beta cell dysfunction is pivotal to the development of diabetes, and restoration of insulin action is of primary importance. Here, we present a review of the mechanism of insulin secretion by pancreatic beta cells and discuss the mutual interaction of signaling pathways in stimulus-secretion coupling to better understand the scientific basis of pharmacological treatment for insulin secretion deficiency. Glucose stimulates insulin secretion via membrane depolarization by closure of ATP-sensitive K(+) channels (K(ATP) channels) and opening of L-type voltage-dependent Ca(2+) channels. The resultant elevation of cytosolic free Ca(2+) triggers insulin exocytosis. This is termed the "K(ATP)-dependent pathway" and is shared by sulfonylurea, which closes K(ATP) channels. Glucose also stimulates insulin release independent of its action on K(ATP) channels. This is referred to as the "K(ATP)-independent pathway," the molecular basis of which remains elusive. In the pancreatic beta cell, incretin hormones increase cAMP level, which enhances glucose-stimulated insulin release by protein kinase A-dependent and -independent mechanisms. Importantly, cAMP does not directly augment Ca(2+)-stimulated insulin release per se. The stimulatory level of ambient glucose is an absolute requirement for incretin to enhance insulin release. Therefore, incretin/cAMP enhances K(ATP)-independent insulinotropic action of glucose. The robust glucose-lowering effect of DPP4 inhibitor add-on in diabetic patients with sulfonylurea secondary failure is intriguing. With the clinical availability of DPP4 inhibitor and GLP-1 mimetics, the importance of the interactions between cAMP signaling and K(ATP) channel-independent actions of glucose is reappraised. ©The Japan Endocrine Society

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21701075     DOI: 10.1507/endocrj.ej11-0064

Source DB:  PubMed          Journal:  Endocr J        ISSN: 0918-8959            Impact factor:   2.349


  6 in total

1.  Loss of Cyclin-dependent Kinase 2 in the Pancreas Links Primary β-Cell Dysfunction to Progressive Depletion of β-Cell Mass and Diabetes.

Authors:  So Yoon Kim; Ji-Hyeon Lee; Matthew J Merrins; Oksana Gavrilova; Xavier Bisteau; Philipp Kaldis; Leslie S Satin; Sushil G Rane
Journal:  J Biol Chem       Date:  2017-01-18       Impact factor: 5.157

Review 2.  Sweet Taste Signaling: The Core Pathways and Regulatory Mechanisms.

Authors:  Sunil Kumar Sukumaran; Salin Raj Palayyan
Journal:  Int J Mol Sci       Date:  2022-07-26       Impact factor: 6.208

Review 3.  Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes.

Authors:  Joseph M Tibaldi
Journal:  Adv Ther       Date:  2014-02-15       Impact factor: 3.845

4.  Efficacy of combination therapy with sitagliptin and low-dose glimepiride in Japanese patients with type 2 diabetes.

Authors:  Hiroaki Ishii; Yosuke Ohkubo; Masahiro Takei; Shinichi Nishio; Masanori Yamazaki; Mieko Kumagai; Yoshihiko Sato; Satoru Suzuki; Yuji Aoki; Takahide Miyamoto; Tomoko Kakizawa; Takahiro Sakuma; Mitsuhisa Komatsu
Journal:  J Clin Med Res       Date:  2014-02-06

Review 5.  Type 2 diabetes, PUFAs, and vitamin D: their relation to inflammation.

Authors:  Ana L Guadarrama-López; Roxana Valdés-Ramos; Beatríz E Martínez-Carrillo
Journal:  J Immunol Res       Date:  2014-02-24       Impact factor: 4.818

6.  Clinical Characteristics and Metabolic Predictors of Rapid Responders to Dipeptidyl Peptidase-4 Inhibitor as an Add-on Therapy to Sulfonylurea and Metformin.

Authors:  Ye An Kim; Won Sang Yoo; Eun Shil Hong; Eu Jeong Ku; Kyeong Seon Park; Soo Lim; Young Min Cho; Kyong Soo Park; Hak Chul Jang; Sung Hee Choi
Journal:  Diabetes Metab J       Date:  2015-11-27       Impact factor: 5.376

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.